Müge Güçsavaş‐Çalıkoğlu

A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)

Joseph Muenzer, J. E. Wraith, Michael Beck et al. · Genetics in Medicine · 2006 · 585 citations · Full text

Life Sciences, Biochemistry, Enzymology +10

Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome

Joseph Muenzer, Michael Beck, Christine M. Eng et al. · Genetics in Medicine · 2010 · 232 citations · Full text

Life Sciences, Biochemistry, Enzymology +1

A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)

Joseph Muenzer, Müge Güçsavaş‐Çalıkoğlu, Shawn E. McCandless et al. · Molecular Genetics and Metabolism · 2006 · 215 citations

Life Sciences, Biochemistry, Clinical Biochemistry +8

Expanding spectrum of congenital disorder of glycosylation Ig (CDG‐Ig): Sibs with a unique skeletal dysplasia, hypogammaglobulinemia, cardiomyopathy, genital malformations, and early lethality

Christian Kranz, Alice Basinger, Müge Güçsavaş‐Çalıkoğlu et al. · American Journal of Medical Genetics Part A · 2007 · 93 citations

Medicine, Genetics, Pediatrics +15

Mitochondrial NADP(H) deficiency due to a mutation in NADK2 causes dienoyl-CoA reductase deficiency with hyperlysinemia

Sander M. Houten, Simone Denis, Heleen te Brinke et al. · Human Molecular Genetics · 2014 · 88 citations · Full text

Life Sciences, Biochemistry, Genetics +17